Prelude Capital Management’s Mesa Laboratories MLAB Stock Holding History

Prelude Capital Management’s Portfolio MLAB Stock Details MLAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$313K	Buy	+3,141	New	+$316K	0.02%	757
2019 Q2	–	Sell	-34	Closed	-$8K	–	1962
2019 Q1	$8K	Buy	+34	New	+$7.68K	﹤0.01%	1528
2015 Q1	–	Sell	-286	Closed	-$22K	–	2067
2014 Q4	$22K	Buy	+286	New	+$20.9K	﹤0.01%	1716
2014 Q3	–	Sell	-400	Closed	-$34K	–	2022
2014 Q2	$34K	Hold	400	–	–	﹤0.01%	1599
2014 Q1	$36K	Buy	+400	New	+$34K	﹤0.01%	1451

Other funds holding MLAB

LPP

Long Path Partners Stamford, Connecticut $235M AUM 22.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

RIM

Ranger Investment Management Dallas, Texas $1.58B AUM 51% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Diamond Hill Capital Management Columbus, Ohio $12.5B AUM 7.49% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Prelude Capital Management's MLAB Position: Q2 2026 in Review

Prelude Capital Management opened a new position in Mesa Laboratories (MLAB) in Q2 2026: 3,141 shares worth $313K. The stake represents 0.02% of the portfolio and ranks #757 among its holdings. This is a return to the name: Prelude Capital Management previously reported a position in MLAB as recently as Q1 2019.

Prelude Capital Management first reported a position in MLAB in Q1 2014 and has held it in 5 quarters since. 159 funds tracked by Wall St. Rank hold MLAB as of Q2 2026.

Prelude Capital Management held 3,141 shares of Mesa Laboratories worth $313K as of Q2 2026.
Mesa Laboratories was a new Prelude Capital Management position in Q2 2026.
Mesa Laboratories made up 0.02% of Prelude Capital Management's portfolio in Q2 2026, its #757 holding.
Prelude Capital Management first reported a position in Mesa Laboratories in Q1 2014 and has held it in 5 quarters since.
159 funds tracked by Wall St. Rank held Mesa Laboratories as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.